Evolva proposes two biotech and food ingredient executives to join its Board

26-Apr-2011 - Switzerland

Evolva Holding SA has published the agenda items for the Annual General Meeting, to be held on 18 May 2011 in Basel. The Board term of Ms. Ingelise Saunders expires at this year’s AGM and she is not up for re-election. Evolva’s Board proposes the shareholders to elect Dr. Stuart Strathdee and Dr. Ganesh Kishore to the Board. Both are current members of the Board of Directors of Abunda Nutrition, Inc. and their election will be subject to the closing of the acquisition of Abunda, foreseen in late Q2 or early Q3, 2011.

Messrs. Strathdee and Kishore bring a wealth of experience from major companies in the industrial biotech and food ingredient industries, and they have profound scientific and commercial expertise particularly with sweeteners, as well as in agricultural biotech.

Dr. Ganesh Kishore has previously been Chief Biotechnology Officer of both Monsanto and DuPont. He was involved in the development of Aspartame (the active ingredient of several major sweetener products) as well as a key agricultural crop protection technology. Dr. Kis­hore is currently CEO of MLSCF, one of the core shareholders of Abunda Nutrition, Inc.

Dr. Stuart Strathdee has held a number of senior management positions at Tate & Lyle, including Group Tre­asurer, Managing Director of several group units and Corporate Develop­ment Director. He was closely involved in the development of Tate & Lyle’s sucralose ingredient business as well as in various acquisitions and other growth initiatives. Dr. Strathdee is an independent director of Abunda, not representing any of Abunda’s shareholders.

Apart from the Board elections and the standard agenda items, Evolva will propose the shareholders to increase both the authorised and conditional capital available in the company’s Articles of Association. These increases will allow the company to issue new shares for the intended acquisition of Abunda, for the exercise of employee options as well as for potential future financing purposes.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances